TTLL11

Summary

TTLL11 (tubulin tyrosine ligase like 11, HGNC:18113) is a protein-coding gene on chromosome 9q33.2, encoding Tubulin polyglutamylase TTLL11 (Q8NHH1). Polyglutamylase which modifies tubulin, generating polyglutamate side chains of variable lengths on the gamma-carboxyl group of specific glutamate residues within the C-terminal tail of tubulin.

Predicted to enable tubulin binding activity and tubulin-glutamic acid ligase activity. Predicted to be involved in microtubule cytoskeleton organization. Predicted to act upstream of or within microtubule severing and protein polyglutamylation. Predicted to be located in cytosol. Predicted to be active in ciliary basal body.

Source: NCBI Gene 158135 — RefSeq curated summary.

At a glance

• GWAS associations: 14
• Clinical variants (ClinVar): 117 total
• MANE Select transcript: NM_001139442

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:18113
Approved symbol	TTLL11
Name	tubulin tyrosine ligase like 11
Location	9q33.2
Locus type	gene with protein product
Status	Approved
Aliases	bA244O19.1
Ensembl gene	ENSG00000175764
Ensembl biotype	protein_coding
OMIM	620694
Entrez	158135

Gene structure

Transcript identifiers

Ensembl transcripts: 10 — 5 protein_coding, 3 protein_coding_CDS_not_defined, 2 nonsense_mediated_decay

ENST00000321582, ENST00000373776, ENST00000373778, ENST00000411790, ENST00000474723, ENST00000486362, ENST00000487468, ENST00000685478, ENST00000687938, ENST00000882246

RefSeq mRNA: 4 — MANE Select: NM_001139442 NM_001139442, NM_001386831, NM_001386833, NM_194252

CCDS: CCDS48012, CCDS6834

Canonical transcript exons

ENST00000321582 — 9 exons

Exon	Start	End
ENSE00001725722	122031723	122031856
ENSE00001729651	121815674	121822879
ENSE00003558395	121989195	121989770
ENSE00003559221	121974884	121974979
ENSE00003562868	121860337	121860443
ENSE00003621013	121870497	121870748
ENSE00003656625	121974009	121974124
ENSE00003729403	122039272	122039368
ENSE00003918396	122092687	122093308

Expression profiles

Bgee: expression breadth ubiquitous, 176 present calls, max score 89.98.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 8.0370 / max 200.4495, expressed in 1697 samples.

FANTOM5 promoters (6 alternative TSS)

Promoter ID	TPM avg	Samples expressed
102376	6.5256	1615
102377	1.0503	628
102373	0.2327	82
102372	0.1818	88
102371	0.0333	15
102370	0.0133	5

Top tissues by expression

249 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
C1 segment of cervical spinal cord	UBERON:0006469	89.98	gold quality
tibialis anterior	UBERON:0001385	87.26	silver quality
spinal cord	UBERON:0002240	87.06	gold quality
muscle of leg	UBERON:0001383	85.25	gold quality
gastrocnemius	UBERON:0001388	85.11	gold quality
hindlimb stylopod muscle	UBERON:0004252	84.32	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	83.65	gold quality
popliteal artery	UBERON:0002250	82.89	gold quality
tibial artery	UBERON:0007610	82.86	gold quality
smooth muscle tissue	UBERON:0001135	82.64	gold quality
aorta	UBERON:0000947	82.45	gold quality
thoracic aorta	UBERON:0001515	82.28	gold quality
muscle layer of sigmoid colon	UBERON:0035805	82.26	gold quality
ascending aorta	UBERON:0001496	82.18	gold quality
prefrontal cortex	UBERON:0000451	82.05	gold quality
descending thoracic aorta	UBERON:0002345	81.94	gold quality
lower esophagus muscularis layer	UBERON:0035833	81.78	gold quality
lower esophagus	UBERON:0013473	81.75	gold quality
right coronary artery	UBERON:0001625	81.36	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	81.06	gold quality
cortical plate	UBERON:0005343	80.77	gold quality
left testis	UBERON:0004533	79.87	gold quality
left coronary artery	UBERON:0001626	79.39	gold quality
right testis	UBERON:0004534	78.85	gold quality
cerebellar hemisphere	UBERON:0002245	78.31	gold quality
right frontal lobe	UBERON:0002810	78.28	gold quality
cerebellar cortex	UBERON:0002129	78.18	gold quality
mucosa of stomach	UBERON:0001199	78.16	gold quality
anterior cingulate cortex	UBERON:0009835	78.07	gold quality
right hemisphere of cerebellum	UBERON:0014890	78.00	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	3.30

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

27 targeting TTLL11, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-103A-3P	99.98	69.14	1595
HSA-MIR-107	99.98	69.14	1595
HSA-MIR-5688	99.96	73.23	4504
HSA-MIR-495-3P	99.96	72.81	4197
HSA-MIR-3682-5P	99.93	67.97	1163
HSA-MIR-6715A-3P	99.83	68.05	1473
HSA-MIR-4649-3P	99.56	66.90	1783
HSA-MIR-7162-5P	99.46	68.08	1368
HSA-MIR-516A-3P	99.46	67.96	1378
HSA-MIR-516B-3P	99.46	67.96	1378
HSA-MIR-5589-3P	99.29	68.30	1443
HSA-MIR-4758-3P	99.12	63.96	869
HSA-MIR-655-5P	98.74	65.93	888
HSA-MIR-7158-3P	98.46	66.45	728
HSA-MIR-4733-3P	98.35	65.20	994
HSA-MIR-6773-3P	98.17	65.51	1213
HSA-MIR-4294	97.86	65.72	1110
HSA-MIR-665	97.60	65.64	1781
HSA-MIR-3189-5P	97.55	66.71	655
HSA-MIR-1226-3P	97.51	66.32	1063
HSA-MIR-5699-5P	97.36	67.03	1014
HSA-MIR-2467-5P	97.36	67.71	991
HSA-MIR-7976	95.75	65.67	1186
HSA-MIR-24-1-5P	95.57	65.85	492
HSA-MIR-24-2-5P	95.57	66.16	484
HSA-MIR-638	83.93	64.46	66

Literature-anchored findings (GeneRIF, showing 2)

• Genetic variant of TTLL11 gene and subsequent ciliary defects are associated with idiopathic scoliosis in a 5-generation UK family. (PMID:34040021)
• TTLL11 gene is associated with sustained attention performance and brain networks: A genome-wide association study of a healthy Chinese sample. (PMID:36511133)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	ttll11	ENSDARG00000060374
mus_musculus	Ttll11	ENSMUSG00000026885
rattus_norvegicus	Ttll11	ENSRNOG00000019339
caenorhabditis_elegans		WBGENE00019230

Paralogs (12): TTLL1 (ENSG00000100271), TTLL12 (ENSG00000100304), TTLL2 (ENSG00000120440), TTLL9 (ENSG00000131044), TTLL4 (ENSG00000135912), TTLL7 (ENSG00000137941), TTLL8 (ENSG00000138892), TTLL10 (ENSG00000162571), TTLL6 (ENSG00000170703), KPRP (ENSG00000203786), TTLL13 (ENSG00000213471), TTLL3 (ENSG00000214021)

Protein

Protein identifiers

Tubulin polyglutamylase TTLL11 — Q8NHH1 (reviewed: Q8NHH1)

Alternative names: Tubulin–tyrosine ligase-like protein 11

All UniProt accessions (5): Q8NHH1, A0A087WU58, A0A087WUG8, A0A087WVF6, A0AA75MRL2

UniProt curated annotations — full annotation on UniProt →

Function. Polyglutamylase which modifies tubulin, generating polyglutamate side chains of variable lengths on the gamma-carboxyl group of specific glutamate residues within the C-terminal tail of tubulin. Preferentially mediates ATP-dependent polyglutamate long side-chain elongation over the initiation step of the polyglutamylation reaction. Preferentially modifies the alpha-tubulin tail over a beta-tail. Required for CCSAP localization to both spindle and cilia microtubules. Promotes tubulin polyglutamylation which stimulates spastin/SPAST-mediated microtubule severing, thereby regulating microtubule functions.

Subcellular location. Cytoplasm. Cytoskeleton. Cilium basal body.

Domain organisation. The flexible c-MTBD (cationic microtubule binding domain) region mediates binding to microtubules. It is positively charged and becomes ordered when bound to microtubules: it interacts with a negatively charged patch on tubulin. The presence of positive charges in the c-MTBD region is essential for proper binding. Gln-345 is the main determinant for regioselectivity, which segregates between initiases and elongases in all tubulin–tyrosine ligase family. A glutamine residue at this position is found in elongases TTLL6, TTLL9, TTLL11, TTLL13, TTLL10 and favors glutamate-chain elongation, whereas an arginine residue is found in initiases TTLL2, TTLL4, TTLL5, TTLL3, TTLL8 and favors initiation.

Similarity. Belongs to the tubulin–tyrosine ligase family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q8NHH1-1	1	yes
Q8NHH1-2	2

RefSeq proteins (3): NP_001132914, NP_001373760, NP_919228 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR004344	TTL/TTLL_fam	Family

Pfam: PF03133

Catalyzed reactions (Rhea), 2 shown:

• L-glutamyl-[protein] + L-glutamate + ATP = gamma-L-glutamyl-L-glutamyl-[protein] + ADP + phosphate + H(+) (RHEA:60144)
• (L-glutamyl)(n)-gamma-L-glutamyl-L-glutamyl-[protein] + L-glutamate + ATP = (L-glutamyl)(n+1)-gamma-L-glutamyl-L-glutamyl-[protein] + ADP + phosphate + H(+) (RHEA:60148)

UniProt features (28 total): binding site 15, compositionally biased region 4, region of interest 3, splice variant 2, chain 1, domain 1, site 1, mutagenesis site 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
9HQ4	ELECTRON MICROSCOPY	3.28

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8NHH1-F1	78.04	0.55

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 255 (essential for specifying alpha-elongation versus initiation step of the polyglutamylase activity)

Ligand- & substrate-binding residues (15): 255–256; 255; 282–285; 295–297; 321; 343–344; 345; 346; 365; 428; 441; 441 …

Mutagenesis-validated functional residues (1):

Position	Phenotype
488–491	decreased binding to microtubules and polyglutamylase activity; when associated with e-326 and e-329.

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-8955332	Carboxyterminal post-translational modifications of tubulin

MSigDB gene sets: 88 (showing top): GSE45365_NK_CELL_VS_CD8A_DC_MCMV_INFECTION_UP, GSE45365_NK_CELL_VS_CD8A_DC_UP, DARWICHE_SKIN_TUMOR_PROMOTER_UP, DARWICHE_PAPILLOMA_RISK_LOW_DN, DARWICHE_PAPILLOMA_RISK_HIGH_DN, DARWICHE_SQUAMOUS_CELL_CARCINOMA_UP, GOCC_MICROTUBULE_ORGANIZING_CENTER, RICKMAN_TUMOR_DIFFERENTIATED_WELL_VS_POORLY_DN, GGARNTKYCCA_UNKNOWN, GOBP_PEPTIDYL_GLUTAMIC_ACID_MODIFICATION, GOMF_LIGASE_ACTIVITY_FORMING_CARBON_NITROGEN_BONDS, GOMF_ACID_AMINO_ACID_LIGASE_ACTIVITY, YY1_01, GCCATNTTG_YY1_Q6, GOCC_CILIUM

GO Biological Process (3): microtubule cytoskeleton organization (GO:0000226), microtubule severing (GO:0051013), protein modification process (GO:0036211)

GO Molecular Function (8): ATP binding (GO:0005524), tubulin binding (GO:0015631), metal ion binding (GO:0046872), tubulin-glutamic acid ligase activity (GO:0070740), protein-glutamic acid ligase activity, initiating (GO:0106437), protein-glutamic acid ligase activity, elongating (GO:0106438), nucleotide binding (GO:0000166), ligase activity (GO:0016874)

GO Cellular Component (7): cytosol (GO:0005829), microtubule (GO:0005874), ciliary basal body (GO:0036064), cytoplasm (GO:0005737), cytoskeleton (GO:0005856), cilium (GO:0005929), cell projection (GO:0042995)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Post-translational protein modification	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
protein-glutamic acid ligase activity	3
cellular anatomical structure	3
cytoskeleton organization	1
microtubule-based process	1
microtubule cytoskeleton organization	1
protein metabolic process	1
macromolecule modification	1
adenyl ribonucleotide binding	1
purine ribonucleoside triphosphate binding	1
cytoskeletal protein binding	1
cation binding	1
nucleoside phosphate binding	1
heterocyclic compound binding	1
catalytic activity	1
cytoplasm	1
microtubule cytoskeleton	1
polymeric cytoskeletal fiber	1
microtubule organizing center	1
cilium	1
intracellular anatomical structure	1
intracellular membraneless organelle	1
intraciliary transport particle	1
membrane-bounded organelle	1
plasma membrane bounded cell projection	1

Protein interactions and networks

STRING

552 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
TTLL11	TTLL12	Q14166	664
TTLL11	LCN9	Q8WX39	534
TTLL11	TTLL5	Q6EMB2	532
TTLL11	ZSCAN20	P17040	509
TTLL11	Q5T8A5	Q5T8A5	508
TTLL11	TTLL1	O95922	483
TTLL11	TRMT10B	Q6PF06	483
TTLL11	SPAST	Q9UBP0	476
TTLL11	ZNF362	Q5T0B9	476
TTLL11	AGBL5	Q8NDL9	474
TTLL11	SACK1E	Q2M2I3	465
TTLL11	DAB2IP	Q5VWQ8	462
TTLL11	TTLL9	Q3SXZ7	462
TTLL11	POC5	Q8NA72	456
TTLL11	PSMD5	Q16401	455
TTLL11	TMEM214	Q6NUQ4	455

IntAct

6 interactions, top by confidence:

A	B	Type	Score
TTLL11	Dlg4	psi-mi:“MI:0407”(direct interaction)	0.440
HSCB	RBP5	psi-mi:“MI:0914”(association)	0.350
MAPT	SHTN1	psi-mi:“MI:0914”(association)	0.350

BioGRID (7): TTLL11 (Affinity Capture-RNA), TTLL11 (Affinity Capture-RNA), TTLL11 (Affinity Capture-RNA), TTLL11 (Affinity Capture-MS), TTLL11 (Affinity Capture-MS), TTLL11 (Affinity Capture-MS), TTLL11 (Affinity Capture-MS)

ESM2 similar proteins: A4FUF0, A4Q9F4, D2XV59, E1C1R4, O94888, O95267, P42694, P54198, P79987, Q15139, Q49A26, Q4R8V9, Q4SS66, Q562D5, Q5R372, Q5R5M3, Q5R7T2, Q5RDU9, Q5REY7, Q5RKH0, Q5RKN4, Q5T6S3, Q5ZIA0, Q5ZJ17, Q5ZLS2, Q5ZLS7, Q61666, Q62101, Q6DC64, Q6DFV5, Q6P5G6, Q6ZPY2, Q6ZWH5, Q70Z35, Q75Q39, Q80VL1, Q86W50, Q8BY87, Q8BYN5, Q8CIW5

Diamond homologs: A2APC3, A4Q9E4, A4Q9E5, A4Q9E8, A4Q9F0, A4Q9F1, A4Q9F4, A4Q9F6, A6NNM8, A6PVC2, A8CVX7, A8X9V4, B2GUB3, E9P886, F7E540, H2KZM9, O95922, P38160, P38584, Q09647, Q0VC71, Q14679, Q1ECV4, Q23AS2, Q23K29, Q23MT7, Q23SI8, Q3SXZ7, Q3SZH6, Q564U4, Q5PPI9, Q5R978, Q641W7, Q6EEF3, Q6EMB2, Q6ZT98, Q80UG8, Q8CHB8, Q8N841, Q8NG68

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

117 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	105
Likely benign	5
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

2721 predictions. Top by Δscore:

Variant	Effect	Δscore
9:121822875:CATCC:C	acceptor_gain	1.0000
9:121870493:TGA:T	donor_loss	1.0000
9:121870494:GAC:G	donor_loss	1.0000
9:121870495:A:AT	donor_loss	1.0000
9:121870576:T:TA	donor_gain	1.0000
9:121870746:GAC:G	acceptor_gain	1.0000
9:121870746:GACCT:G	acceptor_gain	1.0000
9:121870747:ACCTG:A	acceptor_gain	1.0000
9:121870749:C:CC	acceptor_gain	1.0000
9:121870750:T:C	acceptor_loss	1.0000
9:121974007:A:AC	donor_gain	1.0000
9:121974008:C:CT	donor_gain	1.0000
9:121974008:CT:C	donor_gain	1.0000
9:121974008:CTG:C	donor_gain	1.0000
9:121974008:CTGA:C	donor_gain	1.0000
9:121989769:ACCT:A	acceptor_loss	1.0000
9:121989772:T:G	acceptor_loss	1.0000
9:122031718:TCTAC:T	donor_loss	1.0000
9:122031719:CTA:C	donor_loss	1.0000
9:122031720:TAC:T	donor_loss	1.0000
9:122031721:AC:A	donor_loss	1.0000
9:122031722:C:CA	donor_loss	1.0000
9:122031857:C:CC	acceptor_gain	1.0000
9:122039273:TGGAA:T	donor_gain	1.0000
9:122092681:CCTCA:C	donor_loss	1.0000
9:122092682:CTCA:C	donor_loss	1.0000
9:122092683:TCA:T	donor_loss	1.0000
9:122092684:CAC:C	donor_loss	1.0000
9:122092685:A:AG	donor_loss	1.0000
9:122092685:ACCT:A	donor_gain	1.0000

AlphaMissense

5237 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
9:121974048:A:G	L571P	1.000
9:121974054:T:A	D569V	1.000
9:121974966:T:A	D518V	1.000
9:121974966:T:G	D518A	1.000
9:121989369:T:A	K455N	1.000
9:121989369:T:G	K455N	1.000
9:121989432:G:C	N434K	1.000
9:121989432:G:T	N434K	1.000
9:121989495:A:C	C413W	1.000
9:121989622:A:T	V371D	1.000
9:122039282:G:C	N273K	1.000
9:122039282:G:T	N273K	1.000
9:122039332:A:G	W257R	1.000
9:122039332:A:T	W257R	1.000
9:122092695:A:G	W242R	1.000
9:122092695:A:T	W242R	1.000
9:122092721:A:G	L233P	1.000
9:121870509:C:G	R664P	0.999
9:121870510:G:T	R664S	0.999
9:121870635:A:G	L622P	0.999
9:121870635:A:T	L622H	0.999
9:121974055:C:G	D569H	0.999
9:121974071:T:A	K563N	0.999
9:121974071:T:G	K563N	0.999
9:121974912:G:T	P536H	0.999
9:121974927:T:A	E531V	0.999
9:121974960:A:G	L520P	0.999
9:121974965:G:C	D518E	0.999
9:121974965:G:T	D518E	0.999
9:121974966:T:C	D518G	0.999

dbSNP variants (sampled 300 via entrez): RS1000006713 (9:121856506 T>A), RS1000009527 (9:122057781 G>A,C), RS1000011735 (9:121843935 A>G), RS1000015114 (9:122082456 A>G), RS1000037547 (9:121889579 T>C), RS1000054477 (9:121850622 T>C), RS1000054713 (9:121884343 C>T), RS1000076913 (9:121927297 T>C), RS1000092212 (9:121968679 C>G,T), RS1000101404 (9:121897672 G>C), RS1000107773 (9:122009686 AT>A), RS1000108070 (9:121884541 G>A,C), RS1000119492 (9:121838941 C>T), RS1000127784 (9:121850849 C>T), RS1000137972 (9:121984741 A>G)

Disease associations

OMIM: gene MIM:620694 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

14 associations (top):

Study	Trait	p-value
GCST001588_11	Periodontal microbiota	5.000000e-07
GCST005141_67	Cognitive ability (MTAG)	7.000000e-09
GCST005246_6	Inhibitory control	3.000000e-06
GCST005316_63	Intelligence (MTAG)	3.000000e-09
GCST008338_2	Blood cell traits (multivariate analysis)	3.000000e-08
GCST008595_136	Cognitive ability, years of educational attainment or schizophrenia (pleiotropy)	2.000000e-09
GCST009524_297	Household income (MTAG)	1.000000e-09
GCST009524_34	Household income (MTAG)	5.000000e-10
GCST009524_68	Household income (MTAG)	1.000000e-10
GCST010725_17	Malaria	5.000000e-06
GCST010725_29	Malaria	1.000000e-06
GCST010725_96	Malaria	9.000000e-07
GCST010988_406	Adult body size	2.000000e-09
GCST90000047_200	Age at first sexual intercourse	4.000000e-08

EFO canonical traits (12, from GWAS)

EFO ID	Trait name
EFO:0004337	intelligence
EFO:0004784	self reported educational attainment
EFO:0008467	behavioural inhibitory control measurement
EFO:0004305	erythrocyte count
EFO:0004309	platelet count
EFO:0004528	mean corpuscular hemoglobin concentration
EFO:0004833	neutrophil count
EFO:0004842	eosinophil count
EFO:0005090	basophil count
EFO:0005091	monocyte count
EFO:0009695	household income
EFO:0009749	age at first sexual intercourse measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

28 total (human), top 28 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, increases expression, affects expression	5
bisphenol A	affects cotreatment, decreases methylation, decreases expression	2
sodium arsenite	affects cotreatment, increases abundance, increases expression	2
Cyclosporine	decreases expression, increases expression	2
bisphenol F	affects cotreatment, decreases expression	1
triphenyl phosphate	affects expression	1
ethyl-p-hydroxybenzoate	increases expression	1
manganese chloride	increases expression, affects cotreatment, increases abundance	1
CGP 52608	affects binding, increases reaction	1
perfluoro-n-nonanoic acid	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
dorsomorphin	increases expression, affects cotreatment	1
jinfukang	affects cotreatment, decreases expression	1
(+)-JQ1 compound	decreases expression	1
Resveratrol	affects cotreatment, decreases expression	1
Fulvestrant	decreases methylation, affects cotreatment	1
Acetaminophen	increases expression	1
Arsenic	increases abundance, increases expression, affects cotreatment	1
Cisplatin	affects cotreatment, decreases expression	1
Copper	affects cotreatment, decreases expression	1
Dexamethasone	decreases expression, affects cotreatment	1
Doxorubicin	decreases expression	1
Estradiol	increases expression	1
Indomethacin	affects cotreatment, decreases expression	1
Manganese	affects cotreatment, increases abundance, increases expression	1
1-Methyl-3-isobutylxanthine	affects cotreatment, decreases expression	1
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	decreases expression	1
S-Nitrosoglutathione	decreases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.